(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of -46.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12%.
Bicycle Therapeutics's revenue in 2026 is $83,528,000.On average, 12 Wall Street analysts forecast BCYC's revenue for 2026 to be $1,100,962,704, with the lowest BCYC revenue forecast at $183,435,373, and the highest BCYC revenue forecast at $2,733,376,304. On average, 12 Wall Street analysts forecast BCYC's revenue for 2027 to be $477,899,262, with the lowest BCYC revenue forecast at $0, and the highest BCYC revenue forecast at $2,207,953,472.
In 2028, BCYC is forecast to generate $1,116,032,863 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,503,524,144.